BioMarin Pharmaceutical Inc.
BMRNHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, BioMarin Pharmaceutical Inc. (BMRN) is listed under Biotechnology. With a market capitalization of $11.52B, it sits in large-cap territory. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Market Cap
$11.52B
Beta
0.24
P/E (TTM)
42.87
P/E (Fwd)
9.27
EPS (TTM)
$1.39
EPS (Fwd)
$6.43
ROE
4.5%
ROA
4.5%
Cash
$2.22B
Total Debt
$1.44B
Free CF
$459.4M
52W Change
4.0%
Annual Financials
Cash vs Debt
With $2.22B in cash and $1.44B in debt, BMRN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $459.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 4.5%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $2.10B (2022) to $3.22B (2025), reflecting a 54% increase over the period.
With a beta below 0.7, BioMarin Pharmaceutical Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence BioMarin Pharmaceutical Inc.'s trajectory.